Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back.; Severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus. In addition to severe joint pain in upper body including arms, neck and back.; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 50-year-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection), via an unspecified route of administration, administered in left arm on 14Apr2021 (at 08:00) (age at vaccination was 50 years) (Batch/Lot Number: Er8729) as dose 1, single for covid-19 immunization. The patient also received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection), via an unspecified route of administration, administered in right arm on 31May2021 (at 08:00) (age at vaccination was 50 years) (Batch/Lot Number: Ep7534) as dose 2, single for covid-19 immunization.Medical history included colitis ulcerative from an unknown date. Concomitant medications included infliximab (REMICADE), mesalamine (MESALAMINE), venlafaxine hydrochloride (EFFEXOR) taken for an unspecified indication, start and stop date were not reported. The patient had no known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not test COVID-19 positive prior to vaccination. The patient had not been tested for COVID-19 since the vaccination. On 26May2021 (at 11:00)  the patient experienced severe auto immune response including rheumatoid arthritis, inflammation (blood test confirmed), iritis, Necrobiosus.  In addition to severe joint pain in upper body including arms, neck and back. The patient received prednisone as the treatment for the events. The event rheumatoid arthritis was considered as  medically significant. The patient underwent lab tests and procedures which included blood test: unknown results on an unspecified date. The outcome of all the events was resolving.  Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021828042 similar report from same reporter